COMMUNIQUÉS West-GlobeNewswire

-
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
07/03/2024 -
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
07/03/2024 -
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
07/03/2024 -
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
07/03/2024 -
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
07/03/2024 -
Manitoba Harvest Hemp Foods Introduces Protein-Rich Breakfast Staples With New Superseed Instant Oatmeal
07/03/2024 -
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
07/03/2024 -
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
07/03/2024 -
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
07/03/2024 -
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07/03/2024 -
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
07/03/2024 -
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07/03/2024 -
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
07/03/2024 -
LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $8 Million
07/03/2024 -
Le groupe LSL Pharma annonce une combinaison de placements privés pour un produit brut total maximum de 8 millions $
07/03/2024 -
Malaysia Makes Historic Debut in World's Best Hospitals 2024 by Newsweek
07/03/2024 -
BioNTech Announces Planned Retirement of Sean Marett
07/03/2024 -
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
07/03/2024 -
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
07/03/2024
Pages